# Molina Healthcare, Inc.: overview

MOH · NYSE · CIK 1179929 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/moh.md) · [Financials](/companies/moh/financials.md) · [Filings](/companies/moh/filings.md) · [Insiders](/companies/moh/insiders.md)

Latest reported revenue: [$11.08bn](/filings/0001179929-26-000045.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 22, 2026 (XBRL us-gaap:Revenues, accession 0001179929-26-000045).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [10.5 d](/filings/0001179929-26-000005.md) | [11.1](/filings/0001179929-26-000023.md) | [11.4](/filings/0001179929-26-000039.md) | [11.5](/filings/0001179929-26-000045.md) | [11.4 d](/filings/0001179929-26-000005.md) | [10.8](/filings/0001179929-26-000023.md) | [10.9](/filings/0001179929-26-000039.md) | [11.1](/filings/0001179929-26-000045.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [3.6% d](/filings/0001179929-26-000005.md) | [3.9%](/filings/0001179929-26-000023.md) | [3.3%](/filings/0001179929-26-000039.md) | [1.2%](/filings/0001179929-26-000045.md) | [(1.4%) d](/filings/0001179929-26-000005.md) | [0.8%](/filings/0001179929-26-000023.md) | [1.3%](/filings/0001179929-26-000039.md) | [1.0%](/filings/0001179929-26-000045.md) |
| Net margin | % | [2.4% d](/filings/0001179929-26-000005.md) | [2.7%](/filings/0001179929-26-000045.md) | [2.2%](/filings/0001179929-26-000045.md) | [0.7%](/filings/0001179929-26-000045.md) | [(1.4%) d](/filings/0001179929-26-000005.md) | [0.1%](/filings/0001179929-26-000045.md) | [0.6%](/filings/0001179929-26-000045.md) | [0.3%](/filings/0001179929-26-000045.md) |
| Diluted EPS | $ per share | not reported | [5.45](/filings/0001179929-26-000023.md) | [4.75](/filings/0001179929-26-000039.md) | [1.51](/filings/0001179929-26-000045.md) | not reported | [0.27](/filings/0001179929-26-000023.md) | [1.19](/filings/0001179929-26-000039.md) | [0.73](/filings/0001179929-26-000045.md) |
| Free cash flow | $bn | [(0.2) d](/filings/0001179929-26-000005.md) | [0.2](/filings/0001179929-26-000023.md) | [(0.3) d](/filings/0001179929-26-000039.md) | [(0.2) d](/filings/0001179929-26-000045.md) | [(0.3) d](/filings/0001179929-26-000005.md) | [1.1](/filings/0001179929-26-000023.md) | [(0.3) d](/filings/0001179929-26-000039.md) | [(0.2) d](/filings/0001179929-26-000045.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [27.8](/filings/0001179929-24-000033.md) | [32.0](/filings/0001179929-25-000023.md) | [34.1](/filings/0001179929-26-000005.md) | [40.7](/filings/0001179929-26-000005.md) | [45.4](/filings/0001179929-26-000005.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [3.7%](/filings/0001179929-24-000033.md) | [3.7%](/filings/0001179929-25-000023.md) | [4.6%](/filings/0001179929-26-000005.md) | [4.2%](/filings/0001179929-26-000005.md) | [1.7%](/filings/0001179929-26-000005.md) |
| Net margin | % | [2.4%](/filings/0001179929-24-000033.md) | [2.5%](/filings/0001179929-25-000023.md) | [3.2%](/filings/0001179929-26-000005.md) | [2.9%](/filings/0001179929-26-000005.md) | [1.0%](/filings/0001179929-26-000005.md) |
| Diluted EPS | $ per share | [11.25](/filings/0001179929-24-000033.md) | [13.55](/filings/0001179929-25-000023.md) | [18.77](/filings/0001179929-26-000005.md) | [20.42](/filings/0001179929-26-000005.md) | [8.92](/filings/0001179929-26-000005.md) |
| Free cash flow | $bn | [2.0](/filings/0001179929-24-000033.md) | [0.7](/filings/0001179929-25-000023.md) | [1.6](/filings/0001179929-26-000005.md) | [0.5](/filings/0001179929-26-000005.md) | [(0.6)](/filings/0001179929-26-000005.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/moh/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.50bn | 6,572,156 |  | Added +203,130 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $806.9m | 3,560,601 |  | Added +697,208 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $638.1m | 2,790,243 |  | Reduced −728 |
| [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $586.1m | 2,562,913 |  | Reduced −636,433 |
| [Lingotto Investment Management LLP](/funds/1732768.md) | 2026-06-30 | $574.4m | 2,511,490 |  | New +2,511,490 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $538.6m | 2,355,261 |  | Added +45,031 |
| [VICTORY CAPITAL MANAGEMENT INC](/funds/1040188.md) | 2026-06-30 | $453.0m | 1,980,615 |  | Reduced −90,084 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $428.0m | 1,871,290 |  | Reduced −1,333,634 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $401.5m | 1,755,467 |  | Added +25,026 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $318.7m | 1,393,338 |  | Reduced −1,544 |

## Recent filings

[All 1,983 filings](/companies/moh/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-22 | 13:23 ET | [10-Q](/filings/0001179929-26-000045.md) | Quarterly report, period 2026-09-30 | 0001179929-26-000045 |
| 2026-10-21 | 20:18 ET | [8-K](/filings/0001179929-26-000042.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001179929-26-000042 |
| 2026-07-23 | 14:21 ET | [10-Q](/filings/0001179929-26-000039.md) | Quarterly report, period 2026-06-30 | 0001179929-26-000039 |
| 2026-07-22 | 20:20 ET | [8-K](/filings/0001179929-26-000036.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001179929-26-000036 |
| 2026-06-10 | 20:20 ET | [8-K](/filings/0001437749-26-020160.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-020160 |
| 2026-05-11 | 13:02 ET | [8-K](/filings/0001179929-26-000026.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001179929-26-000026 |
| 2026-05-08 | 13:00 ET | [8-K](/filings/0001437749-26-015766.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-015766 |
| 2026-04-23 | 14:11 ET | [10-Q](/filings/0001179929-26-000023.md) | Quarterly report, period 2026-03-31 | 0001179929-26-000023 |
| 2026-04-22 | 20:20 ET | [8-K](/filings/0001179929-26-000020.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001179929-26-000020 |
| 2026-03-23 | 20:18 ET | [DEF 14A](/filings/0001179929-26-000014.md) | Proxy statement, period 2026-03-23 | 0001179929-26-000014 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001179929-26-000005.md), filed Feb 10, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1179929
- Tickers: MOH
- Exchange: NYSE
- SIC code: 6324 Hospital & Medical Service Plans
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.